March 7th 2024
FDA has published final guidance documents regarding validation and development of analytical procedures.
FDA Notifies Genentech of Violations at Avastin Plant
November 10th 2011On Sept. 27, 2011, FDA sent Genentech a Form 483 listing several violations at the company's South San Francisco, California, plant. The violations included problems with investigations into batch failures, inappropriate equipment design, and insufficient protection against contamination. FDA visited the plant, which produces the cancer drug Avastin, 13 times in September 2011 and made four observations.
The Role of Bioburden in the Contamination-Control Plan
January 19th 2011A company's contamination-control plan is an important document designed to formalize the rationale, methods, and validation of contamination-control procedures in a manufacturing facility. The author describes the role of bioburden in the contamination-control plan.